Physician profile
Beverly Cho
NPI 1851751069
$1,304.66
in general payments reported to CMS, 2019-2025
14 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $182 · 2023: $567 · 2024: $310 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $979 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $978.99 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $269.02 | 2023-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $248.24 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $199.55 | 2023-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Pfizer INC. | $104.11 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.18 | 2022-2025 | Jardiance |
| Irhythm Technologies, INC. | $58.50 | 2023 | Zio Xt Patch |
| Janssen Pharmaceuticals, INC | $53.16 | 2023 | Xarelto |
| Boston Scientific Corporation | $30.57 | 2022 | |
| Merz Pharmaceuticals, LLC | $26.03 | 2024 | Xeomin |
| Hologic Sales and Service, LLC | $25.56 | 2022 | |
| Lilly USA, LLC | $24.11 | 2023 | Taltz |
| Lexicon Pharmaceuticals, INC. | $21.73 | 2023 | Inpefa |
| Alexion Pharmaceuticals, INC. | $20.91 | 2024 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.